Product
89Zr-DFO-Nimotuzumab
1 clinical trial
2 indications
Indication
lung cancerIndication
Colorectal CancerClinical trial
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET)Status: Recruiting, Estimated PCD: 2026-09-01